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Sir, In 2007, we described the clinical features and natural history
of neuroferritinopathy in 41 patients defined at the molecular
genetic level by the presence of EcoN1 restriction digestion site
in exon 4 of FTL (also referred to as FTL1), the gene coding for
the ferritin light polypeptide (Chinnery et al., 2007). Three French
patients in our paper (Cases 13, 36 and 39 in Table 1) had
an identical restriction enzyme banding pattern to the original
Cumbrian neuroferritinopathy family (Curtis et al., 2001). Their
early clinical course (Caparros-Lefebvre et al., 1997) and molecular
genetic analysis (Chinnery et al., 2003) had been previously
described. We recently received a DNA sample to confirm the
diagnosis in a new member of the same French family. Given
the recent description of three new FTL mutations (Vidal et al.,
2004; Maciel et al., 2005; Mancuso et al., 2005; Ohta et al.,
2008), we now sequence exon 4 of FTL to provide a more com-
prehensive molecular diagnostic approach. This showed that the
new French patient had a different mutation, 458dupA, which
segregated with the phenotype in the French family and was
not found in 300 European controls. This mutation creates the
same EcoN1 restriction site as 460dupA described in the original
neuroferritinopathy family (Curtis et al., 2001), and given that
both the French and English pedigrees shared a microsatellite
marker 100 kb telomeric to the FTL mutation (Chinnery et al.,
2003), we originally concluded that the disease in both families
was caused by the same FTL mutation. We now know that this
is not the case.
Here, we provide a more comprehensive description of the
clinical course of the three previously published males
(Caparros-Lefebvre et al., 1997) and the new female case from
the next generation harbouring 458dupA. Although the overall
phenotype was broadly similar to the 38 cases with 460dupA,
there were a number of obvious differences, especially relating
to the disease progression since the original publication
(Caparros-Lefebvre et al., 1997). The patients with 458dupA
developed symptoms between 24 year and 44 years of age,
which is well within the 95% confidence intervals for the 38
cases with 460dupA. They displayed the typical presenting clinical
feature of ‘fixed’ or ‘mobile’ dystonia in one limb, causing writing
difficulties or a gait disorder. Within 2 years, orofacial, pharyngeal
and laryngeal dystonia appeared in all four 458dupA cases leading
to anarthria and severe dysphagia after a mean time of 10 years.
The dystonia remained asymmetrical and did not respond to
L-DOPA in any of the four patients. As with the 460dupA patients
(Chinnery et al., 2007), none of the 458dupA cases developed
spasticity, abnormal tendon reflexes, Babinski signs, abnormal
ocular fundi or marked tremor.
On the other hand, three deceased members of the oldest gen-
eration of the French family with 458dupA eventually developed
cerebellar ataxia. In addition, the new female case in the youngest
generation developed a severe static and locomotor cerebellar
syndrome rendering her wheelchair bound within 10 years.
Although not previously described in the 38 patients with
460dupA (Chinnery et al., 2007), cerebellar ataxia has been
described in other neuroferritinopathy families caused by different
mutations in FTL (Maciel et al., 2005; Mancuso et al., 2005). A
further difference was the rate of clinical progression. 458dupA
doi:10.1093/brain/awn274 Brain 2009: 132; 1–3 | e109
Received September 1, 2008. Revised September 24, 2008. Accepted September 29, 2008. Advance Access publication October 14, 2008
 2008 The Author(s)
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/
2.0/uk/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
was associated with the rapid progression of akineto-rigid syn-
drome in the three males, cerebellar ataxia with hypotonia in
the female and cognitive and behavioral symptoms in all four.
This led to a moderate subcortico-frontal dementia (Mattis
score ranged from 120 to 128/144; mean Mini Mental State
Examination = 24/30, mean Frontal Assessment Battery = 13/18)
with apathy (mean Lille Apathy Rating Scale =8/36,
cutoff 17). Two had a diagnosis of depression. The parkinsonian
syndrome was characterized by no or slight rest tremor, a mild
L-DOPA sensitivity of 30%, an off-UPDRS part III ranging from 30
to 44 and axial involvement responsible for postural instability
and falls. Other atypical features included a limitation of vertical
eye movements and mild dysautonomia (orthostatic hypotension,
constipation, urinary incontinence) developing between 5 years
and 10 years. Two patients had a central apnoea syndrome with
restrictive respiratory insufficiency (Vital Capacity of 64%) causing
excessive daytime sleepiness. In one case this was effectively trea-
ted with non-invasive positive pressure ventilation. All developed
severe weight loss requiring tube feeding after 10 years in three
cases, contributing to death aged 70 years in one. One patient
died from a cardiomyopathy at the age of 60 years. Thus, the
clinical course in the family with 458dupA, with parkinsonism
and dementia, differs from the remaining 38 patients with
460dupA where there was only slight or no parkinsonian features
and a mild decrease in verbal fluency (Chinnery et al., 2007).
Structural MR imaging in the family with 458dupA (Fig. 1A)
revealed iron deposition and cystic cavitation of the basal ganglia
in all patients in a pattern characteristic of neuroferritinopathy
(McNeill et al., 2008). This included the dentate nuclei, where
functional MR showed abnormalities consistent with neuronal dis-
ruption and altered membrane turnover (Fig. 1B). Other clinical
investigations revealed similar results to those published previously
(Chinnery et al., 2007). Serum ferritin levels were below the
normal range in all four cases, despite normal haemoglobin and
serum iron levels. Electromyography, electroretinography and
peripheral nerve conduction studies were normal. Visual evoked
potentials were slightly altered in the two patients tested.
These clinical differences are intriguing, given that both
458dupA and 460dupA disrupt the same restriction site and lead
to a shift in the reading frame which lengthens the ferritin light
polypeptide by four residues. However, the 458dupA allele is
predicted to alter residue 153 from histidine to glutamine, disrupt-
ing the subsequent amino sequence. In contrast, residue 153 is
wild-type in patients with the 460dupA allele, which is predicted
to change residue 154 from an arginine to lysine. Residue 154 is
a glutamine in patients with 458dupA, but the subsequent
amino acid sequence is predicted to be identical for both mutated
alleles. Different neurological and psychiatric features have
been described in one family with a mis-sense mutation in FTL
(c.474G4A/p.A96T) (Maciel et al., 2005) including cerebellar
ataxia. Although it is difficult to reach a firm conclusion at
this stage, our observations in the French family with 458dupA
support the view that subtle differences in a critical region of
the ferritin protein sequence modulate the phenotype of
neuroferritinopathy.
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Figure 1 (A) Axial-T2-weighted image showing high signal within caudate and lenticular nuclei associated with cystic cavitation.
(B) The spectrum acquired with a single voxel technique at long echo time (144 ms) in the deep left cerebellum including the dentate
nucleus shows a decrease of NAA/Cr (1.07) and Cho/Cr (0.68) ratios related to neuronal dysfunction and a disturbance of neuronal
membrane turnover.
e109 | Brain 2009: 132; 1–3 Letter to the Editor
Mancuso M, Davidzon G, Kurlan RM, Tawil R, Bonilla E, Di Mauro S,
et al. Hereditary ferritinopathy: a novel mutation, its cellular
pathology, and pathogenetic insights. J Neuropathol Exp Neurol
2005; 64: 280–94.
McNeill A, Birchall D, Hayflick SJ, Gregory A, Schenk JF, Zimmerman EA,
et al. T2* and FSE MRI distinguishes four subtypes of neuro-
degeneration with brain iron accumulation. Neurology 2008; 70:
1614–19.
Ohta E, Nagasaka T, Shindo K, Toma S, Nagasaka K, Ohta K, et al.
Neuroferritinopathy in a Japanese family with a duplication in the
ferritin light chain gene. Neurology 2008; 70: 1493–4.
Vidal R, Ghetti B, Takao M, Brefel-Courbon C, Uro-Coste E, Glazier BS,
et al. Intracellular ferritin accumulation in neural and extraneural tissue
characterizes a neurodegenerative disease associated with a mutation
in the ferritin light polypeptide gene. J Neuropathol Exp Neurol 2004;
63: 363–80.
Letter to the Editor Brain 2009: 132; 1–3 | e109
